News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Mindset disagrees with and denies the allegations set forth from Reunion.
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Subscribe To Our Newsletter & Stay Updated
